- FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC
- FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer
- FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture
- FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection
- FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
- FDA Approves Avaclyr (acyclovir ophthalmic ointment) for the Treatment of Herpetic Keratitis
- FDA Approves the Reintroduction of Zelnorm (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in Women Under 65
- FDA Approves Asceniv (immune globulin intravenous, human) for Primary Humoral Immunodeficiency
- FDA Approves Duaklir Pressair (aclidinium bromide and formoterol fumarate) for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
- FDA Approves Mavenclad (cladribine) Tablets for Multiple Sclerosis
- FDA Approves Cimzia (certolizumab pegol) for the Treatment for Non-Radiographic Axial Spondyloarthritis
- FDA Approves Jatenzo (testosterone undecanoate) for Certain Forms of Hypogonadism
- FDA Approves Mayzent (siponimod) for Secondary Progressive Multiple Sclerosis
- FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
- FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression